Information Provided By: 
Fly News Breaks for June 20, 2016
EPZM
Jun 20, 2016 | 08:16 EDT
After the overall response rate of refractory non-Hodgkin lymphoma patients taking Epizyme's Tazemetostat came in at 28%, down from 56% and 60% in prior trials, RBC Capital says that the data could improve over time. Specifically, the firm thinks that some of the patients whose tumors shrunk may become responsive over the longer term. Additionally, RBC Capital reports that there was a 100% overall response rate in the FL EZH2 mutant arm of the trial. The firm keeps an Outperform rating on the shares.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
